Lucas Ward

Scott Henry

Do Kim

Guyn Kim

Robert Sassoon

Robert Sessions

- Vivos Therapeutics, Inc. announced **first-time, peer-reviewed data** confirming its Vivos DNA (Daytime-Nighttime Appliance®) is **safe and efficacious** in treating children suffering from obstructive sleep apnea (OSA).  **[1716166_0001493152-25-013953_form8-k.htm:0]** **[1716166_0001493152-25-013953_ex99-1.htm:0]** 
- The multicenter clinical trial results, published in the _European Journal of Pediatrics_, showed that **77% of participants experienced at least a 50% reduction in OSA severity**, with **93% of children with severe OSA achieving this reduction**.  **[1716166_0001493152-25-013953_ex99-1.htm:0]** **[1716166_0001493152-25-013953_ex99-1.htm:1]** 
- The study also reported that **17% of patients achieved complete resolution of their OSA**, and airway volume increased by an average of **67.8%**.  **[1716166_0001493152-25-013953_ex99-1.htm:1]** 
- These results position the Vivos DNA appliance as a **safe, non-surgical alternative** for pediatric OSA treatment, contrasting with the current invasive surgical standard of care.  **[1716166_0001493152-25-013953_ex99-1.htm:1]**

Vivos Therapeutics (VVOS)